文献速递心脑血管急症

急性心肌梗死后常规使用螺内酯

Routine Spironolactone in Acute Myocardial Infarction.
PubMed 文献 · N Engl J Med · 2024-11-17
一句话结论急性心梗PCI术后患者常规使用螺内酯未降低心血管死亡或新发/恶化心衰复合终点发生率(HR 0.96,95%CI 0.81–1.13)。

该多中心2×2析因设计试验纳入7062例心梗并行经皮冠状动脉介入治疗的患者,随机接受螺内酯或安慰剂(同时随机接受秋水仙碱或安慰剂),本文报告螺内酯部分结果。中位随访3年,第一主要终点(心血管死亡或新发/恶化心衰总事件数)螺内酯组183起事件(1.7/100患者年)vs 安慰剂组220起(2.1/100患者年),校正竞争风险HR 0.91(95%CI 0.69–1.21,P=0.51)。第二主要终点(心梗、卒中、新发/恶化心衰或心血管死亡首次发生)螺内酯组280/3537例(7.9%)vs 安慰剂组294/3525例(8.3%),校正竞争风险HR 0.96(95%CI 0.81–1.13,P=0.60)。严重不良事件螺内酯组255例(7.2%)vs 安慰剂组241例(6.8%)。

要点

  • 心梗PCI术后患者常规使用螺内酯未降低心血管死亡或新发/恶化心衰总事件数:183起(1.7/100患者年)vs 220起(2.1/100患者年),校正竞争风险HR 0.91(95%CI 0.69–1.21,P=0.51)。
  • 第二主要终点(心梗、卒中、新发/恶化心衰或心血管死亡首次发生)螺内酯组7.9%(280/3537)vs 安慰剂组8.3%(294/3525),校正竞争风险HR 0.96(95%CI 0.81–1.13,P=0.60),无显著差异。
  • 严重不良事件螺内酯组7.2%(255例)vs 安慰剂组6.8%(241例)。
  • 该试验为多中心2×2析因设计,纳入7062例心梗行PCI患者,104个中心、14个国家,中位随访3年。
  • 分析时45例(0.6%)生命状态未知。

适用人群与场景

  • 心肌梗死并接受经皮冠状动脉介入治疗的患者,共7062例,来自104个中心、14个国家。

处置流程与药物剂量

  • 患者随机接受螺内酯或安慰剂,同时按2×2析因设计随机接受秋水仙碱或安慰剂;本文报告螺内酯部分结果。

研究设计与关键结果

  • 多中心2×2析因设计试验,纳入7062例心梗行PCI患者,螺内酯组3537例、安慰剂组3525例,中位随访3年。
  • 第一主要终点(心血管死亡或新发/恶化心衰复合终点,按总事件数评估):螺内酯组183起事件(1.7/100患者年)vs 安慰剂组220起事件(2.1/100患者年),校正非心血管死亡竞争风险HR 0.91(95%CI 0.69–1.21,P=0.51)。
  • 第二主要终点(心梗、卒中、新发/恶化心衰或心血管死亡首次发生):螺内酯组280/3537例(7.9%)vs 安慰剂组294/3525例(8.3%),校正竞争风险HR 0.96(95%CI 0.81–1.13,P=0.60)。
  • 严重不良事件:螺内酯组255例(7.2%)vs 安慰剂组241例(6.8%)。
  • 分析时45例(0.6%)生命状态未知。

证据类型、等级与局限

  • 证据类型:多中心随机对照试验(2×2析因设计)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者结论认为,在心梗患者中,螺内酯未降低心血管死亡或新发/恶化心衰的发生率,也未降低心血管死亡、心梗、卒中或新发/恶化心衰复合终点发生率。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Mineralocorticoid receptor antagonists have been shown to reduce mortality in patients after myocardial infarction with congestive heart failure. Whether routine use of spironolactone is beneficial after myocardial infarction is uncertain.

METHODS: In this multicenter trial with a 2-by-2 factorial design, we randomly assigned patients with myocardial infarction who had undergone percutaneous coronary intervention to receive either spironolactone or placebo and either colchicine or placebo. The results of the spironolactone trial are reported here. The two primary outcomes were a composite of death from cardiovascular causes or new or worsening heart failure, evaluated as the total number of events; and a composite of the first occurrence of myocardial infarction, stroke, new or worsening heart failure, or death from cardiovascular causes. Safety was also assessed.

RESULTS: We enrolled 7062 patients at 104 centers in 14 countries; 3537 patients were assigned to receive spironolactone and 3525 to receive placebo. At the time of our analyses, the vital status was unknown for 45 patients (0.6%). For the first primary outcome, there were 183 events (1.7 per 100 patient-years) in the spironolactone group as compared with 220 events (2.1 per 100 patient-years) in the placebo group over a median follow-up period of 3 years (hazard ratio adjusted for competing risk of death from noncardiovascular causes, 0.91; 95% confidence interval [CI], 0.69 to 1.21; P = 0.51). With respect to the second primary outcome, an event occurred in 280 of 3537 patients (7.9%) in the spironolactone group and 294 of 3525 patients (8.3%) in the placebo group (hazard ratio adjusted for competing risk, 0.96; 95% CI, 0.81 to 1.13; P = 0.60). Serious adverse events were reported in 255 patients (7.2%) in the spironolactone group and 241 (6.8%) in the placebo group.

CONCLUSIONS: Among patients with myocardial infarction, spironolactone did not reduce the incidence of death from cardiovascular causes or new or worsening heart failure or the incidence of a composite of death from cardiovascular causes, myocardial infarction, stroke, or new or worsening heart failure. (Funded by the Canadian Institutes of Health Research and others; CLEAR ClinicalTrials.gov number, NCT03048825.).

来源:N Engl J Med,查看原文。版权归原作者所有。

参考来源

  1. Jolly SS, d'Entremont MA, Pitt B, et al. Routine Spironolactone in Acute Myocardial Infarction. N Engl J Med. 2024. PMID: 39555814. doi:10.1056/NEJMoa2405923

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。